Fresno, California 93720

  • Psoriasis


The main purpose of this study is to characterize the long-term safety and efficacy of the drug BMS-986165 in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.


Inclusion Criteria: - Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis - Women must not be pregnant, lactating, or breastfeeding Exclusion Criteria: - Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study. - To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.



Primary Contact:

Rachel Peterson
Phone: +1 619 293 6213

Backup Contact:


Location Contact:

Fresno, California 93720
United States

Regina Hamlin, Site 0206
Phone: 559-432-6457

Site Status: Recruiting

Data Source:

Date Processed: September 28, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.